“Swing Factors” Will Heavily Influence GSK Growth In ’08, Chief Exec Garnier Says
Outcome of a plan to jumpstart sales of Avandia and FDA approval of Cervarix are two key issues that will impact GSK in the new year.
Outcome of a plan to jumpstart sales of Avandia and FDA approval of Cervarix are two key issues that will impact GSK in the new year.